Drug discovery is an expensive proposition, with a $2.6 billion cost over 10 years and just a 12% success rate. AI promises to significantly improve the success rate by finding small molecule hits for undruggable targets. On the forefront …
Read More
Matt Rasmussen, VP of Software Engineering at insitro, expands on his first post on redun, insitro’s data science tool for bioinformatics, to describe how redun makes use of advanced AWS features. Specifically, Matt describes how AWS …
Read More
Matt Rasmussen, VP of Software Engineering at insitro describes their recently released, open-source data science framework, redun, which allows data scientists to define complex scientific workflows that scale from their laptop to …
Read More
Quantum physics and high-performance computing have slashed research times for a consortium of researchers led by Qubit Pharmaceuticals. This post describes the discovery of chemical substances that may lead to new COVID-19 treatments in …
Read More
We recently launched two new Amazon EC2 instance families based on Intel’s Ice Lake – the C6i and M6i. These instances provide higher core counts and take advantage of generational performance improvements on Intel’s Xeon scalable processor …
Read More
We have been working with a team of researchers at the Max Planck Institute, helping them adopt the AWS cloud for drug research applications in the pharmaceutical industry. In this post, we’ll focus on how the team at Max Planck obtained …
Read More
This blog provides an overview of NVIDIA’s Clara Parabricks along with a guide on how to use Parabricks within the AWS Marketplace. It focuses on germline analysis for whole genome and whole exome applications using GPU accelerated bwa-mem …
Read More
OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems, used Yellowdog on AWS to analyze and screen 337 million compounds in 7 hours, a task which would have taken two months using an …
Read More